On August 23, 2024, MAPS submitted a Formal Dispute Resolution Request to appeal the Clinical Hold placed on the Phase 2 study of cannabis for Veterans with PTSD (MJP2) by the FDA Division of Psychiatry …
FOR IMMEDIATE RELEASE: August 9, 2024 Aug 9, 2024 – San Jose, CA – The Multidisciplinary Association for Psychedelic Studies (MAPS) is evaluating the path forward for safe, legal access to MDMA-assisted …
The History of SB 1012 Following Measure 109‘s success in November 2020 in Oregon, California Senator Scott Wiener introduced SB519 in January 2021. California Governor Gavin Newsom eventually vetoed …
Richard Nixon announced the War on Drugs in 1971 and, in doing so, perpetuated an ongoing rhetoric and myth of Black criminality. Ronald Reagan escalated the impact of this policy by prioritizing punishment …
Evidence demonstrates, and the general public believes, cannabis should be legal for adult use. President Biden has repeatedly promised to decriminalize cannabis, but even before the President’s proclamation, …
Join MAPS leaders Kris Lotlikar, Ismail Ali, J.D., Allison Coker, Ph.D., and Betty Aldworth to delve into the approaches and strategies MAPS is engaging during this critical juncture. After 38 years of …
Dear Friends and Allies, On June 4, 2024, the U.S. Food and Drug Administration (FDA) convened a meeting of the Psychopharmacologic Drugs Advisory Committee to evaluate Lykos Therapeutics’ (Lykos) New …
The first half of 2024 has been riveting for a few reasons. By now, Oregon’s regulated access program has been in effect for eighteen months, with thousands of people having received psilocybin services; …
The Multidisciplinary Association for Psychedelic Studies (MAPS) and Momentum Events are pleased to announce the successful conclusion of their professional collaboration following the groundbreaking Psychedelic …
By Betty Aldworth • MAPS Bulletin: Volume XXIX Number 1 • 2019 …
Statement from MAPS We have closely examined the facts behind the stories recounted in the recent Business Insider article. We stand behind our work and the work of our independent affiliates Lykos Therapeutics …
